CAJ | 학술논문

目的：比较观察厄洛替尼与培美曲塞在晚期非小细胞肺癌（ NSCLC）维持治疗中的疗效及毒副反应。方法纳入72例晚期NSCLC患者，一线治疗均给予含铂双药标准一线方案化疗，能顺利完成4周期化疗且病情得到控制者共42例，然后随机均分为2组，分别给予厄洛替尼及培美曲塞维持治疗，比较观察2组的生存情况和毒副反应。结果厄洛替尼组、培美曲塞组的中位无进展生存时间分别为5.8个月、5.5个月，差异无统计学意义（ P﹥0.05）。厄洛替尼组主要毒副反应为皮疹和腹泻，培美曲塞组主要毒副反应为消化道反应和血液学毒性，2组骨髓抑制、恶心呕吐、皮疹发生率比较差异有统计学意义（ P﹤0.05）。结论厄洛替尼与培美曲塞作为维持治疗方法治疗晚期NSCLC在延长生存期方面作用相似，但厄洛替尼的毒副反应更轻，患者更易于耐受。
목적：비교관찰액락체니여배미곡새재만기비소세포폐암（ NSCLC）유지치료중적료효급독부반응。방법납입72례만기NSCLC환자，일선치료균급여함박쌍약표준일선방안화료，능순리완성4주기화료차병정득도공제자공42례，연후수궤균분위2조，분별급여액락체니급배미곡새유지치료，비교관찰2조적생존정황화독부반응。결과액락체니조、배미곡새조적중위무진전생존시간분별위5.8개월、5.5개월，차이무통계학의의（ P﹥0.05）。액락체니조주요독부반응위피진화복사，배미곡새조주요독부반응위소화도반응화혈액학독성，2조골수억제、악심구토、피진발생솔비교차이유통계학의의（ P﹤0.05）。결론액락체니여배미곡새작위유지치료방법치료만기NSCLC재연장생존기방면작용상사，단액락체니적독부반응경경，환자경역우내수。
Objective To compare the efficacy and toxicities between erlotinib and pemetrexed for in the mainte-nance therapy of advanced non-small cell lung cancer( NSCLC ). Methods Seventy-two patients with advanced NSCLC were treated with platinum-based double standard regimen as the first-line drug regimen. 42 patients with disease control after 4 cycles of chemotherapy,was divided into two groups,were given erlotinib and pemetrexed for maintenance therapy separately,the survival and toxicities of the two groups were compared. Results The median progression-free survival time of the erlotinib group was 5. 8 months,and was 5. 5 months of the pemetrexed group (P﹥0. 05). The major toxicities of erlotinib were rash and diarrhea,those of pemetrexed were gastrointestinal reac-tion and haematological toxicities,there were statistically significant differences in the incidence of marrow depres-sion,nausea and vomiting,rash showed between the two groups(P﹤0. 05). Conclusion The survival of erlotinib and pemetrexed is similar in the maintenance treatment of advanced NSCLC,but the toxicities of erlotinib are milder than pemetrexed.